These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 31558478)

  • 1. Comprehensive Transcriptomic Profiling Identifies Breast Cancer Patients Who May Be Spared Adjuvant Systemic Therapy.
    Sjöström M; Chang SL; Fishbane N; Davicioni E; Hartman L; Holmberg E; Feng FY; Speers CW; Pierce LJ; Malmström P; Fernö M; Karlsson P
    Clin Cancer Res; 2020 Jan; 26(1):171-182. PubMed ID: 31558478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicogenomic Radiotherapy Classifier Predicting the Need for Intensified Locoregional Treatment After Breast-Conserving Surgery for Early-Stage Breast Cancer.
    Sjöström M; Chang SL; Fishbane N; Davicioni E; Zhao SG; Hartman L; Holmberg E; Feng FY; Speers CW; Pierce LJ; Malmström P; Fernö M; Karlsson P
    J Clin Oncol; 2019 Dec; 37(35):3340-3349. PubMed ID: 31618132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and Validation of a Genomic Profile for the Omission of Local Adjuvant Radiation in Breast Cancer.
    Sjöström M; Fyles A; Liu FF; McCready D; Shi W; Rey-McIntyre K; Chang SL; Feng FY; Speers CW; Pierce LJ; Holmberg E; Fernö M; Malmström P; Karlsson P
    J Clin Oncol; 2023 Mar; 41(8):1533-1540. PubMed ID: 36599119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays.
    Albain KS; Paik S; van't Veer L
    Breast; 2009 Oct; 18 Suppl 3():S141-5. PubMed ID: 19914534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).
    Bueno-de-Mesquita JM; van Harten WH; Retel VP; van 't Veer LJ; van Dam FS; Karsenberg K; Douma KF; van Tinteren H; Peterse JL; Wesseling J; Wu TS; Atsma D; Rutgers EJ; Brink G; Floore AN; Glas AM; Roumen RM; Bellot FE; van Krimpen C; Rodenhuis S; van de Vijver MJ; Linn SC
    Lancet Oncol; 2007 Dec; 8(12):1079-1087. PubMed ID: 18042430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subtype-Specific Metagene-Based Prediction of Outcome after Neoadjuvant and Adjuvant Treatment in Breast Cancer.
    Callari M; Cappelletti V; D'Aiuto F; Musella V; Lembo A; Petel F; Karn T; Iwamoto T; Provero P; Daidone MG; Gianni L; Bianchini G
    Clin Cancer Res; 2016 Jan; 22(2):337-45. PubMed ID: 26423797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 38-gene expression signature to predict metastasis risk in node-positive breast cancer after systemic adjuvant chemotherapy: a genomic substudy of PACS01 clinical trial.
    Jézéquel P; Campone M; Roché H; Gouraud W; Charbonnel C; Ricolleau G; Magrangeas F; Minvielle S; Genève J; Martin AL; Bataille R; Campion L
    Breast Cancer Res Treat; 2009 Aug; 116(3):509-20. PubMed ID: 19020972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial).
    Penault-Llorca F; Filleron T; Asselain B; Baehner FL; Fumoleau P; Lacroix-Triki M; Anderson JM; Yoshizawa C; Cherbavaz DB; Shak S; Roca L; Sagan C; Lemonnier J; Martin AL; Roché H
    BMC Cancer; 2018 May; 18(1):526. PubMed ID: 29728098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinesin family member-18A (KIF18A) is a predictive biomarker of poor benefit from endocrine therapy in early ER+ breast cancer.
    Alfarsi LH; Elansari R; Toss MS; Diez-Rodriguez M; Nolan CC; Ellis IO; Rakha EA; Green AR
    Breast Cancer Res Treat; 2019 Jan; 173(1):93-102. PubMed ID: 30306428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EarlyR: A Robust Gene Expression Signature for Predicting Outcomes of Estrogen Receptor-Positive Breast Cancer.
    Buechler SA; Gökmen-Polar Y; Badve SS
    Clin Breast Cancer; 2019 Feb; 19(1):17-26.e8. PubMed ID: 30097312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast carcinoma with an Oncotype Dx recurrence score <18: Rate of distant metastases in a large series with clinical follow-up.
    Wen HY; Krystel-Whittemore M; Patil S; Pareja F; Bowser ZL; Dickler MN; Norton L; Morrow M; Hudis CA; Brogi E
    Cancer; 2017 Jan; 123(1):131-137. PubMed ID: 27526056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging immune gene signatures as prognostic or predictive biomarkers in breast cancer.
    Kwon MJ
    Arch Pharm Res; 2019 Nov; 42(11):947-961. PubMed ID: 31707598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
    Skarlos P; Christodoulou C; Kalogeras KT; Eleftheraki AG; Bobos M; Batistatou A; Valavanis C; Tzaida O; Timotheadou E; Kronenwett R; Wirtz RM; Kostopoulos I; Televantou D; Koutselini E; Papaspirou I; Papadimitriou CA; Pectasides D; Gogas H; Aravantinos G; Pavlidis N; Arapantoni P; Skarlos DV; Fountzilas G
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):533-46. PubMed ID: 21901395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study.
    Iwata H; Masuda N; Yamamoto Y; Fujisawa T; Toyama T; Kashiwaba M; Ohtani S; Taira N; Sakai T; Hasegawa Y; Nakamura R; Akabane H; Shibahara Y; Sasano H; Yamaguchi T; Sakamaki K; Bailey H; Cherbavaz DB; Jakubowski DM; Sugiyama N; Chao C; Ohashi Y
    Breast Cancer Res Treat; 2019 Jan; 173(1):123-133. PubMed ID: 30242578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic predictor of residual risk of recurrence after adjuvant chemotherapy and endocrine therapy in high risk estrogen receptor-positive breast cancers.
    Khan SS; Karn T; Symmans WF; Rody A; Müller V; Holtrich U; Becker S; Pusztai L; Hatzis C
    Breast Cancer Res Treat; 2015 Feb; 149(3):789-97. PubMed ID: 25651779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 16 Yin Yang gene expression ratio signature for ER+/node- breast cancer.
    Xu W; Jia G; Cai N; Huang S; Davie JR; Pitz M; Banerji S; Murphy L
    Int J Cancer; 2017 Mar; 140(6):1413-1424. PubMed ID: 27925180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence.
    Ignatiadis M; Azim HA; Desmedt C; Veys I; Larsimont D; Salgado R; Lyng MB; Viale G; Leyland-Jones B; Giobbie-Hurder A; Kammler R; Dell'Orto P; Rothé F; Laïos I; Ditzel HJ; Regan MM; Piccart M; Michiels S; Sotiriou C
    JAMA Oncol; 2016 Feb; 2(2):217-24. PubMed ID: 26633571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomics of adjuvant therapy for breast cancer.
    Kim SR; Paik S
    Cancer J; 2011; 17(6):500-4. PubMed ID: 22157294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline.
    Henry NL; Somerfield MR; Abramson VG; Ismaila N; Allison KH; Anders CK; Chingos DT; Eisen A; Ferrari BL; Openshaw TH; Spears PA; Vikas P; Stearns V
    J Clin Oncol; 2019 Aug; 37(22):1965-1977. PubMed ID: 31206315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant chemotherapy in early breast cancer.
    Ejlertsen B
    Dan Med J; 2016 May; 63(5):. PubMed ID: 27127018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.